Evidence review: Open Peptide Project (verified against primary PubMed, ClinicalTrials.gov & FDA records) · Last checked 2026-10-27. ← Back to Evidence Library

Bacteriostatic water and sterility risks

Name: Bacteriostatic water and sterility risks
Published: 2026-10-27

Why "bacteriostatic" does not mean sterile forever, and what the label and USP actually say

Evidence verdict: Bacteriostatic Water for Injection is an FDA-approved diluent with specific label limits. Contamination of multi-use injectables is a well-documented cause of bloodstream infections.

Last reviewed: Oct 27, 2026

In 30 seconds

Bacteriostatic water contains benzyl alcohol, a preservative that slows bacterial growth. It does not sterilize a contaminated product. [Regulatory]
The FDA label warns that benzyl alcohol has been linked to toxicity in newborns and that it should not be used for neonates. [Regulatory]
A 2025 review of 50 outbreak reports found contaminated IV fluids and medicines caused bloodstream infections with a median case-fatality of 21.1%. [Observational]
USP <797> sets the standards for sterile compounding in pharmacies. Home handling does not meet them.

What the label says

The label for Bacteriostatic Water for Injection, USP (NDA 018802) says it is indicated only for diluting or dissolving drugs according to the instructions of the manufacturer of the drug being given. It warns that benzyl alcohol has been associated with toxicity in neonates, that only preservative-free Sterile Water for Injection should be used for neonatal products, and that giving it intravenously without a solute may cause hemolysis. [Regulatory] This page gives no preparation or volume instructions.

Bacteriostatic is not sterile

A preservative inhibits growth of some organisms. It cannot remove organisms or endotoxin already introduced, and it does not make a non-sterile powder sterile. Endotoxin is a heat-stable bacterial toxin that preservatives do not neutralize (see the endotoxin guide). [Regulatory, Lab]

What outbreaks show

A 2025 scoping review of 50 articles on culture-confirmed outbreaks from contaminated infusates found a median of 12 patients per outbreak and a median case-fatality ratio of 21.1%. Half of the implicated non-nutrition fluids and medicines had been used incorrectly as multidose containers, and a third were contaminated at the source (PMID 40156049). [Observational] These were health-care settings in lower-income countries; data for home use of gray-market peptides are not available (UNVERIFIED).

The standard that applies to pharmacies

USP General Chapter <797> sets requirements for compounding sterile preparations, including facilities, garbing, aseptic technique and beyond-use dates. Licensed compounders are expected to follow it; there is no equivalent safeguard for products sold for research use only. [Regulatory]

Evidence levels used on this page

[Regulatory] FDA, USP or WADA primary document. [Controlled study] randomized trial or systematic review of trials. [Observational] market surveillance, pharmacovigilance or cohort data. [Lab] cell, analytical or animal work. [Case] single case report.

Endotoxins and TFA salts, Peptide degradation, storage and cold chain

References

Bacteriostatic Water for Injection, USP, prescribing label (NDA 018802), via openFDA drug label API / DailyMed.
United States Pharmacopeia. General Chapter <797> Pharmaceutical Compounding: Sterile Preparations. https://www.usp.org/compounding/general-chapter-797
Nyandwaro K, et al. Healthcare-associated bloodstream infections caused by contamination of intravenous fluids and medicines in LMIC facilities: a scoping review. Antimicrob Resist Infect Control. 2025. PMID 40156049.

Disclaimer: This page is for education only. It is not medical advice, and it does not endorse using, buying or preparing any unapproved product. Talk to a licensed clinician before you start, stop or change any treatment.